Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function

Cancer Research

Volumn 65, Issue 19, 2005, Pages 8690-8697

  Patel, Nilay S ^a,b   Li, Ji Liang ^a   Generali, Daniele ^a   Poulsom, Richard ^c   Cranston, David W ^b   Harris, Adrian L ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; DELTA LIKE 4 LIGAND; EPHRIN B2; HEY1 PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LIGAND; NOTCH RECEPTOR; PROTEIN; PROTEIN P21; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; EMBRYO DEVELOPMENT; ENDOTHELIUM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN SITU HYBRIDIZATION; KIDNEY CANCER; KIDNEY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION;

BLOOD PROTEINS; CELL GROWTH PROCESSES; CELL HYPOXIA; CELL MOVEMENT; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMANS; IN SITU HYBRIDIZATION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RNA, SMALL INTERFERING; UMBILICAL VEINS; UP-REGULATION;

EID: 25444506836     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-1208     Document Type: Article

References (47)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
2. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47.
3. Artavanis-Tsakonas S, Matsuno K, Fortini ME. Notch signaling. Science 1995;268:225-32.
4. Weinmaster G. The ins and outs of notch signaling. Mol Cell Neurosci 1997;9:91-102.
5. Radtke F, Raj K. The role of Notch in tumorigenesis: oncogene or tumour suppressor? Nat Rev Cancer 2003;3:756-67.
6. Mumm JS, Kopan R. Notch signaling: from the outside in. Dev Biol 2000;228:151-65.
7. Weinmaster G. Notch signaling: direct or what? Curr Opin Genet Dev 1998;8:436-42.
8. Nakagawa O, McFadden DG, Nakagawa M, et al. Members of the HRT family of basic helix-loop-helix proteins act as transcriptional repressors downstream of Notch signaling. Proc Natl Acad Sci U S A 2000;97:13655-60.
9. Davis RL, Turner DL. Vertebrate hairy and Enhancer of split related proteins: transcriptional repressors regulating cellular differentiation and embryonic patterning. Oncogene 2001;20:8342-57.
10. Iso T, Kedes L, Hamamori Y. HES and HERP families: multiple effectors of the Notch signaling pathway. J Cell Physiol 2003;194:237-55.
11. Iso T, Hamamori Y, Kedes L. Notch signaling in vascular development. Arterioscler Thromb Vasc Biol 2003;23:543-53.
12. Duarte A, Hirashima M, Benedito R, et al. Dosage-sensitive requirement for mouse D114 in artery development. Genes Dev 2004;18:2474-8.
13. Krebs LT, Shutter JR, Tanigaki K, Honjo T, Stark KL, Gridley T. Haploinsufficient lethality and formation of arteriovenous malformations in Notch pathway mutants. Genes Dev 2004;18:2469-73.
14. Gale NW, Dominguez MG, Noguera I, et al. Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. Proc Natl Acad Sci U S A 2004;101:15949-54.
15. Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996;380:439-42.
16. Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996;380:435-9.
17. Mailhos C, Modlich U, Lewis J, Harris A, Bicknell R, Ish-Horowicz D. Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis. Differentiation 2001;69:135-44.
18. Claxton S, Fruttiger M. Periodic delta-like 4 expression in developing retinal arteries. Gene Expr Patterns 2004;5:123-7.
19. O'Hare MJ, Bond J, Clarke C, et al. Conditional immortalization of freshly isolated human mammary fibroblasts and endothelial cells. Proc Natl Acad Sci USA 2001;98:646-51.
20. Brown D, Jarvis R, Pallotta V, Byrom M, Ford L. RNA interference in mammalian cell culture: design, executin and analysis of the siRNA effect. Ambion TechNotes 2002;9:3-5.
21. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:e45.
22. Robertson N, Potter C, Harris AL. Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion. Cancer Res 2004;64:6160-5.
23. Ho PY, Liang YC, Ho YS, Chen CT, Lee WS. Inhibition of human vascular endothelial cells proliferation by terbinafine. Int J Cancer 2004;111:51-9.
24. Suchting S, Heal P, Tahtis K, Stewart LM. Bicknell R. Soluble Robo4 receptor inhibits in vivo angiogenesis and endothelial cell migration. FASEB J 2005;19:121-3.
25. Erzurum VZ, Bian JF, Husak VA, et al. R136K fibroblast growth factor-1 mutant induces heparin-independent migration of endothelial cells through fibrin glue. J Vasc Surg 2003;37:1075-81.
26. Goodwin BL, Solomonson LP, Eichler DC. Arginino-succinate synthase expression is required to maintain nitric oxide production and cell viability in aortic endothelial cells. J Biol Chem 2004;279:18353-60.
27. Sowter HM, Raval RR, Moore JW, Ratcliffe PJ, Harris AL. Predominant role of hypoxia-inducible transcription factor (Hif)-1α versus Hif-2α in regulation of the transcriptional response to hypoxia. Cancer Res 2003;63:6130-4.
28. Turner KJ, Moore JW, Jones A, et al. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res 2002;62:2957-61.
29. Liu ZJ, Shirakawa T, Li Y, et al. Regulation of Notch1 and D114 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis. Mol Cell Biol 2003;23:14-25.
30. Reuter VE, Presti JC, Jr. Contemporary approach to the classification of renal epithelial tumors. Semin Oncol 2000;27:124-37.
31. Herman JG, Latif F, Weng Y, et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A 1994;91:9700-4.
32. Gnarra JR, Tory K, Weng Y, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994;7:85-90.
33. Noseda M, Chang L, McLean G, et al. Notch activation induces endothelial cell cycle arrest and participates in contact inhibition: role of p21Cip1 repression. Mol Cell Biol 2004;24:8813-22.
34. Nakatsu MN, Sainson RC, Aoto JN, et al. Angiogenic sprouting and capillary lumen formation modeled by human umbilical vein endothelial cells (HUVEC) in fibrin gels: the role of fibroblasts and Angiopoietin-1. Microvasc Res 2003;66:102-12.
35. Taylor KL, Henderson AM, Hughes CC. Notch activation during endothelial cell network formation in vitro targets the basic HLH transcription factor HESR-1 and down-regulates VEGFR-2/KDR expression. Microvasc Res 2002;64:372-83.
36. Lawson ND, Vogel AM, Weinstein BM. sonic hedgehog and vascular endothelial growth factor act upstream of the Notch pathway during arterial endothelial differentiation. Dev Cell 2002;3:127-36.
37. Nanus DM, Schmitz-Drager BJ, Motzer RJ, et al. Expression of basic fibroblast growth factor in primary human renal tumors: correlation with poor survival. J Natl Cancer Inst 1993;85:1597-9.
38. MacKenzie F, Duriez P, Wong F, Noseda M, Karsan A. Notch4 inhibits endothelial apoptosis via RBP-JK-dependent and -independent pathways. J Biol Chem 2004;279:11657-63.
39. Shawber CJ, Das I, Francisco E, Kitajewski J. Notch signaling in primary endothelial cells. Ann N Y Acad Sci 2003;995:162-70.
40. 1 checkpoint controls in telomerase-immortalized endothelial cells. Cell Cycle 2004;3:811-6.
41. Bruhl T, Heeschen C, Aicher A, et al. p21Cip1 levels differentially regulate turnover of mature endothelial cells, endothelial progenitor cells, and in vivo neovascularization. Circ Res 2004;94:686-92.
42. Yeh JR, Mohan R, Crews CM. The antiangiogenic agent TNP-470 requires p53 and p21CIP/WAF for endothelial cell growth arrest. Proc Natl Acad Sci USA 2000;97:12782-7.
43. Krebs LT, Xue Y, Norton CR, et al. Notch signaling is essential for vascular morphogenesis in mice. Genes Dev 2000;14:1343-52.
44. Uyttendaele H, Ho J, Rossant J, Kitajewski J. Vascular patterning defects associated with expression of activated Notch4 in embryonic endothelium. Proc Natl Acad Sci U S A 2001;98:5643-8.
45. Henderson AM, Wang SJ, Taylor AC, Aitkenhead M, Hughes CC. The basic helix-loop-helix transcription factor HESR1 regulates endothelial cell tube formation. J Biol Chem 2001;276:6169-76.
46. MacKenzie F, Duriez P, Larrivee B, et al. Notch4-induced inhibition of endothelial sprouting requires the ankyrin repeats and involves signaling through RBP-JK. Blood 2004;104:1760-8.
47. Leong KGI, Hu X, Li L, et al. Activated Notch4 inhibits angiogenesis: role of β1-integrin activation. Mol Cell Biol 2002;22:2830-41.